Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.01 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.01 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
by Zacks Equity Research
Clearside Biomedical (CLSD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 64.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -59.02% and 2.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Clearside Biomedical (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -21.43% and 76.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 88.10% and 28.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 10.78% and 6.95%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5.63% and 1.57%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 10.17% and 44.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.14% and 98.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of -27.40% and 119.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 74.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 26.67% and 79.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0% and 48.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -333.33% and 96.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 244.44% and 95.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?